PharmAust given go-ahead to continue Human Cancer Trial

THE ROADHOUSE PHARMACY: PharmAust Limited (ASX: PAA) has received formal approval from the Royal Adelaide Hospital Research Ethics Committee to continue with its trial with PPL-1 in late stage human cancer patients.

The company said principal investigator, Professor Michael Brown with support from CMAX will re-initiate screening to identify patients for the trial.

It has also been confirmed the first patient treated in the trial will be ‘replaced’ by the next patient recruited, enabling three patients to be recruited and treated with the lowest dose of PPL-1 for 28 days, as specified in the protocol.

“This is a reassuring outcome and we look forward to continuing with assessment of PPL-1 in this ‘first in man’ trial,” PharmAust executive chairman Dr Roger Aston said in the company’s announcement to the Australian Securities Exchange.

“Furthermore, we will report as soon as the next patient begins treatment with PPL-1.

“The drug will be potentially administered to patients suffering from diverse cancers.

“Recruitment will include selection of patients suffering from lung, pancreas, oesophageal, gastric, colorectal, ovarian, breast, prostate, liver, sarcoma, lymphoma, and melanoma.”

Website: www.pharmaust.com